Faron Pharmaceuticals Ltd.
Tykistökatu 6 B, BioCity
Turku
FIN-20520
Tel: 358-2-469-5151
Fax: 358-2-469-5152
Website: http://www.faronpharmaceuticals.com/
63 articles about Faron Pharmaceuticals Ltd.
-
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting - September 22, 2023
9/22/2023
Faron Pharmaceuticals Ltd. announces that the extraordinary general meeting of the Company took place , September 22, 2023 in Turku, Finland.
-
Faron Pharmaceuticals Announces Board Changes - September 22, 2023
9/22/2023
Faron Pharmaceuticals Ltd. is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier.
-
Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
9/21/2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces the appointment of Dr. Birge Berns, MD, as the Company’s interim Chief Medical Officer.
-
Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/6/2023
Faron Pharmaceuticals Ltd. announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023.
-
Faron Reports Half-Year Financial Results, January 1 – June 30, 2023
8/29/2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces unaudited half-year financial results for January 1 to June 30, 2023.
-
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
8/29/2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces the U.S. Food and Drug Administration has granted Orphan Drug Designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia.
-
Faron Pharmaceuticals Notice of Half-Year Financial Results
8/4/2023
Faron Pharmaceuticals Ltd will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.
-
Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
8/2/2023
Faron Pharmaceuticals Ltd. announces that the Company’s Chief Executive Officer, Dr. Markku Jalkanen, and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts, in Room Abigail Adams C.
-
Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update
7/19/2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces new positive clinical data from the Company's ongoing Phase I/II BEXMAB study.
-
Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS
7/19/2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study.
-
New biomarker data from BEXMAB study at EHA2023
6/9/2023
Faron Pharmaceuticals Oy announces the release of new biomarker data from the ongoing Phase I/II BEXMAB study of bexmarilimab in combination with standard of care in the aggressive hematological malignancies of acute myeloid leukemia and myelodysplastic syndrome.
-
The ASCO Annual Meeting being held in June 3 to 7 will introduce hundreds of posters, abstracts and presentations of cancer studies, preclinical and clinical. BioSpace looks at three presenters.
-
Presentation of Biomarker Analysis at ASCO
5/30/2022
Faron Pharmaceuticals Ltd announces that new biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS trial, will be presented at the upcoming American Society of Clinical Oncology 2022 Annual Meeting being held in Chicago, US from June 3 – 7.
-
Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies
5/16/2022
Faron Pharmaceuticals Ltd. announces that both the U.S. Food and Drug Administration and Finnish Medicines Agency have cleared Faron's Investigational New Drug application to begin the Company sponsored BEXMAB study.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Faron Pharmaceuticals announced a new analysis that estimates 100% overall survival at 12-months for patients who experienced clinical benefit following treatment with bexmarilimab.
-
Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO)
4/21/2022
Faron Pharmaceuticals Ltd announces that results from the melanoma cohort in the ongoing phase I/II MATINS trial, will be presented at the 18th Congress of the European Association of Dermato-Oncology, being held in Seville, Spain, April 21 to April 23, 2022.
-
Financial Statement January 1 to December 31 2021
3/25/2022
Faron Pharmaceuticals Ltd announced audited full-year financial results for January 1 to December 31, 2021 and H2 2021 and provided an overview of recent corporate developments.
-
Presentation of Biomarker Data at AACR - Mar 09, 2022
3/9/2022
Faron Pharmaceuticals Ltd announces that an analysis of biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS trial, will be presented at the upcoming American Association for Cancer Research Annual Meeting being held in New Orleans, US, from April 8 - 13, 2022.
-
Faron Obtains Debt Funding from IPF Partners
2/28/2022
Faron Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has entered into a secured debt agreement with IPF Partners to advance and accelerate its pipeline programs.